drugset / Trial / NCT04354441

Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women

NCT04354441

RandomizedParallel-groupQuadruple-blindTreatment

Summary

COVID-19 was declared a pandemic on March 11th. Efforts to save lives are essential as we will face increasing morbidity with rising demands on health care resources. Since pregnant women with COVID-19 have systematically been excluded from drug trials, potential treatment options for these high-risk individuals remain untested. The aim of our trial is to determine whether hydroxychloroquine given to COVID-19 positive pregnant women can reduce COVID-19-related hospital admissions, thereby allowing women to stay at home while limiting utilization of hospital resources and resulting exposure of health care providers.

Timeline

Start
2020-05
Primary completion
2020-05
Completion
2020-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 200 mg Oral

Indications